Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis
In myelofibrosis patients aged 65 years and above undergoing allogeneic HCT, a favorable 2-year overall survival of 62% was noted with an inferior DFS compared to younger patients, while other post-transplant outcomes remained comparable. These findings support allo-HCT as a viable option in selected elderly MF patients using tailored transplant strategies.
Authors
- Hana Qasim (ORCID: https://orcid.org/0000-0002-9354-6314)
- Mehdi Hamadani (ORCID: https://orcid.org/0000-0001-5372-510X)
- Muhammad Kashif Amin (ORCID: https://orcid.org/0000-0002-4052-7339)
- Iqra Anwar
- Muhammad Umair Mushtaq (ORCID: https://orcid.org/0000-0001-8122-0563)
- Joseph P. McGuirk (ORCID: https://orcid.org/0000-0002-0539-4796)
- Matthew McGuirk
- R. Laila Ahsan
- Abdulraheem Yacoub (ORCID: https://orcid.org/0000-0001-5293-4620)
- Sibgha Gull Chaudhary
- Moazzam Shahzad (ORCID: https://orcid.org/0000-0002-9609-6160)
- Anurag K. Singh (ORCID: https://orcid.org/0000-0002-6703-5115)
- Sohaib Irfan (ORCID: https://orcid.org/0009-0008-3133-5993)
- Muhammad Jawad Javed
Institutions
- Medical College of Wisconsin (US)
- Moffitt Cancer Center (US)
- University of Kansas Medical Center (US)
- Cellular Therapeutics (United Kingdom) (GB)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.clml.2025.08.012
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical College of Wisconsin
- Health Resources and Services Administration
- U.S. Public Health Service
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases